Executive Dysfunction Common in Drug-Resistant Epilepsy, Linked to Unemployment

Individuals with drug-resistant epilepsy (DRE) frequently experience executive dysfunction – difficulties with cognitive processes like planning, problem-solving and organization – and this is associated with a higher likelihood of unemployment, according to recent research. This highlights the significant impact DRE has beyond just seizure control, affecting patients’ quality of life and ability to maintain employment.

Understanding Drug-Resistant Epilepsy

Epilepsy affects over 51 million people worldwide, with more than 4.9 million new cases diagnosed each year. The primary treatment for epilepsy is antiseizure medications (ASMs). However, approximately one-third of individuals with epilepsy do not achieve adequate seizure control despite appropriate ASM use, a condition known as drug-resistant epilepsy (DRE).

The Link Between DRE and Executive Dysfunction

Recent studies demonstrate a strong correlation between DRE and executive dysfunction. This means that individuals with DRE often struggle with cognitive skills essential for daily life and work. These skills include:

• Planning and organization
• Working memory
• Cognitive flexibility
• Inhibition of impulsive behaviors

ASM Load and Executive Dysfunction

The severity of executive dysfunction appears to be linked to the number of ASMs a patient is taking. A higher “ASM load” – meaning using more medications or a greater number of different ASMs – is associated with more pronounced cognitive difficulties. This suggests that while ASMs are necessary to control seizures, they can also contribute to cognitive side effects.

Impact on Employment

Executive dysfunction significantly impacts a person’s ability to maintain employment. The cognitive challenges associated with DRE can make it difficult to perform job duties, manage work responsibilities, and navigate workplace demands. Individuals with DRE and executive dysfunction are at a higher risk of unemployment.

Emerging Treatments for Drug-Resistant Epilepsy

While DRE presents a significant challenge, research continues to explore new treatment options. These include emerging ASMs such as cenobamate, fenfluramine, ganaxolone, ezogabine (retigabine), and perampanel, each with unique mechanisms of action. Further investigation into these and other therapies is crucial to improve seizure control and minimize the cognitive impact of DRE.

The Economic Burden of Drug-Resistant Epilepsy

Drug-resistant epilepsy carries a substantial economic burden, not only for healthcare systems but also for individuals and their families. Loss of productivity and employment due to cognitive impairment contribute to this economic impact.

Key Takeaways

• Drug-resistant epilepsy affects approximately one-third of individuals with epilepsy.
• Executive dysfunction is common in people with DRE, impacting cognitive abilities.
• A higher load of antiseizure medications is linked to more severe executive dysfunction.
• Executive dysfunction increases the risk of unemployment in individuals with DRE.
• Ongoing research is focused on developing new treatments to improve outcomes for those with DRE.